Rethinking the role of alpha-synuclein aggregation in the pathogenesis of Parkinson’s disease and synucleinopathies



Hilal Lashuel is the director of the Laboratory of Molecular and Chemical Biology of Neurodegeneration at École polytechnique fédérale de Lausanne (EPFL) in Switzerland. Research in the Lashuel laboratory focuses on applying chemical biology approaches to elucidate the mechanisms of protein misfolding and aggregation and their contribution to neurodegenerative diseases with ultimate goal of developing novel therapies and diagnostics for early intervention, and monitoring disease progression.
Dr. Lashuel received his B.Sc. degree in chemistry from Brooklyn College (1994) and completed his doctoral studies at Texas A&M University and the Scripps Research Institute (2000). He joined Harvard Medical School and the Brigham and Women’s Hospital (2001) as a research fellow and was later promoted to an instructor in neurology before joining the EPFL in 2005. In addition to his appointment at the EPFL, Dr. Lashuel served as the Executive Director of Qatar Biomedical Research, a member of the Board of Trustees for the Qatar Biobank and Qatar Genome Project from 2014-2016, and currently serves as the research, development and innovation advisor to the chairperson of Qatar Foundation. He is also founder and CSO of ND BioSciences SA a biotech company focusing on developing novel diagnostics and therapies to treat neurodegenerative diseases.